drugset / Trial / NCT02499900
Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary objective of this study is to compare patient medication satisfaction as measured by the Medication Satisfaction Questionnaire (MSQ) scores between the Copaxone 40 mg/mL three time a week (TIW) group and the Copaxone 20 mg/mL once daily (QD) group over 6 months of treatment.
Timeline
- Start
- 2015-08-10
- Primary completion
- 2017-01-10
- Completion
- 2017-06-02
Outcome
Met primary endpoint
paper Patients on GA40 were statistically significantly more satisfied with their medication than those on GA20 (LSM difference in MSQ, 0.3; 95% CI, 0.2, 0.5; p<0.001). PMID 31132664 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Glatiramer Acetate | Small molecule | 20 mg/ml | Subcutaneous |
| Subject | Glatiramer Acetate | Small molecule | 40 mg/ml | Subcutaneous |